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Background: Intracerebral infection of susceptible mouse strains with Theiler’s murine encephalomyelitis virus
(TMEV) results in chronic demyelinating disease with progressive axonal loss and neurologic dysfunction similar
to progressive forms of multiple sclerosis (MS). We previously showed that as the disease progresses, a marked
decrease in brainstem N-acetyl aspartate (NAA; metabolite associated with neuronal integrity) concentrations,
reflecting axon health, is measured. We also demonstrated stimulation of neurite outgrowth by a neuron-binding
natural human antibody, IgM12. Treatment with either the serum-derived or recombinant human immunoglobulin M
12 (HIgM12) preserved functional motor activity in the TMEV model. In this study, we examined IgM-mediated changes
in brainstem NAA concentrations and central nervous system (CNS) pathology.
Findings: 1H-magnetic resonance spectroscopy (MRS) showed that treatment with HIgM12 significantly increased
brainstem NAA concentrations compared to controls in TMEV-infected mice. Pathologic analysis demonstrated a
significant preservation of axons in the spinal cord of animals treated with HIgM12.
Conclusions: This study links drug efficacy of slowing deficits with axon preservation and NAA concentrations in
the brainstem in a model of progressive MS. HIgM12-mediated changes of NAA concentrations in the brainstem
are a surrogate marker of axon injury/preservation throughout the spinal cord. This study provides proof-of-concept
that a neuron-reactive human IgM can be therapeutic and provides a biomarker for clinical trials.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating
disease of the central nervous system (CNS). The patho-
genesis of the disease also involves axonal injury. Currently,
there are no FDA-approved drugs that protect neurons and
axons from degeneration. We previously showed that a
human mAb of the IgM isotype, human immunoglobulin* Correspondence: Rodriguez.Moses@mayo.edu
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unless otherwise stated.M 12 (HIgM12), bound to the surface of neurons, sup-
ported robust neurite extension when presented as sub-
strate, and overrode the neurite extension inhibition of
CNS myelin [1]. The Theiler’s murine encephalomyeli-
tis virus (TMEV)-induced model of human demyelinat-
ing disease has been used extensively in our laboratory
as a therapeutic drug discovery platform. This model
was used to screen for the remyelination promoting hu-
man IgM, HIgM22, that recently completed phase I
clinical trial in patients with MS [2]. Using this model,
we also showed that a single dose of HIgM12 improved
clinical disease course of virus-infected mice beginning
at 2 weeks following treatment, which persisted for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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identical biological properties to the serum-derived anti-
body, that is, induced neurite extension and neuronal pro-
tection in vitro [4] and improved neurologic function of
TMEV-infected mice in vivo [5].
Changes in brain metabolites measured by magnetic
resonance spectroscopy (MRS) reflect neurological path-
ology. N-acetyl-aspartate (NAA), a derivative of aspartic
acid, is the second most abundant free amino acid metab-
olite in nervous tissue [6] after glutamate and provides a
prominent peak in MRS readouts in vivo. A representativeFigure 1 A single dose of neuron-binding human antibody improves NAA
spectra collected at the mouse brainstem. N-acetyl-aspartate (NAA) marke
at 90 days post-TMEV infection, the time when NAA levels begin to fall an
HIgM12, isotype IgM control, or PBS i.p. MRS at the brainstem was collecte
concentrations were calculated from the spectra. Compared to pre-treatm
(P < 0.001). NAA in the control IgM-treated group did not change (P = 0.18
(C) After the last MRS measurements, mice were sacrificed, brains remove
(means ± SEM) were similar across treatment groups (P = 0.51). (D) Brainst
score showed no correlation (P = 0.59). (E) Changes in the individual NAA
treatment. NAA levels were considered improved if the difference (NAA10
exact test was performed, and the control IgM-treated group did not differ fro
from both control groups (vs control IgM, P = 0.0001 and vs PBS, P = 0.001).prominent peak of NAA obtained from spectra collected
at the mouse brainstem is shown (Figure 1A). Reduced
NAA concentrations correlated with reduced axonal num-
bers in lesions of secondary progressive MS (SPMS) pa-
tients [7], primary progressive MS (PPMS), and relapsing
remitting MS (RRMS) [8]. Most studies use brain MRS
readouts for diagnostic purposes. Although rare, MRS of
the spinal cord (SC) has been performed in humans [9]
and rats [10]. Studies of MS patients’ showed reduced
NAA levels at cervical SC compared to control humans
[11]. We recently reported that NAA concentrations inconcentrations in the brainstem. (A) A representative 300 MHz, 1H
d to the right is the dominant peak. (B) Groups of 9 to 13 SJL/J mice
d large-axon loss is detectable, were given a single 100 μg dose of
d before and at 5 and 10 weeks following the treatment. NAA
ent, NAA increased in the HIgM12-treated group after 10 weeks
8); in the PBS-treated group, it decreased after 10 weeks (P = 0.027).
d and processed for pathology analysis. Brainstem pathological scores
em NAA concentrations plotted against the brainstem pathological
concentrations were calculated at the final time point versus before
wk − NAAbefore) was higher than or equal to 2 × baseline SEM. Fischer’s
m PBS-treated group (P = 0.388). The HIgM12-treated group differed
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mice mimic disease progression [12].
Treatment of TMEV-infected mice with HIgM22 pro-
moted remyelination that reached maximal levels by
5 weeks after treatment and remained at the same level
10 weeks post-treatment [13]. This suggests that if the
degree of remyelination improved, then the axons them-
selves that are wrapped should be preserved as well. We
hypothesized that MRS at the brainstem may be a viable
endpoint in clinical trials designed to preserve or protect
axons in the spinal cord. To test this idea, we treated
TMEV-infected mice with the neuron-binding HIgM12
antibody and asked whether changes in NAA concentra-
tions serve as a reliable endpoint marker.Methods
Ethics statements
The Mayo Clinic Institutional Animal Care and Use
Committee (IACUC) approved all animal protocols used
in this study.Theiler’s virus model of demyelination
Demyelinating disease was induced in 8-week-old SJL/J
mice by intracerebral injection of 10 μl containing
2.0 × 105 plaque-forming units of Daniel’s strain TMEV.
This resulted in >98% incidence of infection with rare
fatalities [14].Antibodies and treatment
HIgM12 was used as the treatment. A serum-derived
IgM non-reactive to neurons was used as control. SJL
mice at 90 dpi were treated with a single 100 μg intra-
peritoneal dose of HIgM12 or controls (control IgM,
phosphate-buffered saline (PBS)).Magnetic resonance spectroscopy
MRS was performed using a Bruker Avance 300 MHz
(7 T) vertical bore NMR spectrometer (Bruker Biospin,
Billerica, MA, USA). During data acquisition, animal
core temperatures were maintained at 37°C by a flow of
warm air. Inhalational isoflurane anesthesia 1.5% to
2.5% in oxygen was delivered via nose cone. MRS data
were obtained, and NAA concentrations quantified
from a (2.5 × 2.5 × 2.5) mm3 voxel (15.625 μl), placed
over the brainstem as reported previously [12]. MRS
data was collected from each mouse before treatment
and at 5 and 10 weeks later. The same investigator
selected all voxels based on anatomical landmarks to
maintain strict uniformity. Bruker’s VSEL sequence, an
implementation of the standard PRESS sequence, was
used for voxel-based spectroscopy, with built-in water
suppression pulses.Spinal cord morphometry
Spinal cord morphometry was performed according to
the sampling scheme reported previously [12]. We found
that a consistent 1-μm cross-section from any level of
the spinal cord can be used for axon frequency analysis;
however, the T6 level was selected because it is the smal-
lest thoracic spinal cord cross section and has a high
white matter to gray matter ratio [15]. A 1-μm araldite-
embedded section was cut from a mid-thoracic (T6)
block for axonal analysis. Cross sections were stained
with 4% p-phenylenediamine to visualize the myelin
sheaths. Approximately 400,000 μm2 of white matter
was sampled from each mouse. Absolute myelinated
axon numbers were calculated as reported in [16]. Data
were represented as the absolute number of all axons
sampled per mid-thoracic spinal cord section. All
gradings were performed on coded sections without the
knowledge of the experimental group.
Brain pathology
Brain pathology was assessed after the last MRS measure-
ment, using our previously described technique [17]. Fol-
lowing perfusion with Trump’s fixative, we made two
coronal cuts in the intact brain at the time of removal
from the skull (one section through the optic chiasm and
a second section through the infundibulum). As a guide,
we used the Atlas of the Mouse Brain and Spinal Cord
corresponding to sections 220 and 350, page 6 [18]. This
resulted in three blocks that were then embedded in par-
affin and allowed for a systematic analysis of the pathology
of the cortex, corpus callosum, hippocampus, brainstem,
striatum, and cerebellum. Resulting sections were then
stained with hematoxylin and eosin. Pathological scores
were assigned without knowledge of experimental group
to the following areas of the brain: cortex, corpus callo-
sum, hippocampus, brainstem, striatum, and cerebellum.
Each area of the brain was graded on a five-point scale as
follows: 0, no pathology; 1, no tissue destruction but only
minimal inflammation; 2, early tissue destruction (loss of
architecture) and moderate inflammation; 3, definite tissue
destruction (demyelination, parenchymal damage, cell
death, neurophagia, neuronal vacuolation); and 4, necrosis
(complete loss of all tissue elements with associated cellu-
lar debris). Meningeal inflammation was assessed and
graded as follows: 0, no inflammation; 1, one cell layer of
inflammation; 2, two cell layers of inflammation; 3, three
cell layers of inflammation; and 4, four or more cell layers
of inflammation. The area with maximal tissue damage
was used for assessment of each brain region. The data
were expressed as mean ± standard error of the mean.
Data analysis and statistics
Data for NAA concentrations and axon-count analysis
were compared by Student’sT test if normally distributed
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distributed. Groups greater than two were subjected to
one-way ANOVA analysis when they were normally
distributed or to Kruskal-Wallis ANOVA on ranks
when non-normally distributed. In all analyses, P < 0.05
was considered as statistically significant. Correlation
coefficients between paired sets of data were deter-
mined using the Pearson product moment correlation.
Fisher’s exact test was used to compare animals with im-
proved NAA versus those with no change/decrease in NAA
concentrations.Results
To confirm whether HIgM12 preserves neuronal health
in the spinal cords of TMEV-infected mice, we used
brainstem NAA concentrations measured by MRS as a
biomarker. We elected to treat TMEV-infected mice at
90 dpi. At this time, maximal demyelination coincides
with a drop in NAA concentrations. Following collection
of baseline NAA concentrations at 90 dpi, three groups
of 10 to 13 mice received a single intraperitoneal dose of
HIgM12 (100 μg), control human IgM (100 μg), or saline
(PBS). MRS measurements were repeated at 5 and
10 weeks post-treatment. In the control IgM-treated
group, we found no significant differences in NAA
concentrations between baseline and later time points
(P = 0.74, one-way ANOVA). In the PBS-treated group,
10 weeks post-treatment, NAA concentrations were
significantly reduced (P = 0.027, ANOVA on ranks). In
the HIgM12-treated group, we found a significant in-
crease in NAA concentrations at both 5- and 10-week
time points (P < 0.001, one-way ANOVA) (Figure 1B).
Analysis of pathology (cerebellum, cortex, brainstem,
hippocampus, striatum, corpus callosum, and meninges)Figure 2 HIgM12 does not promote spinal cord remyelination but preserv
longitudinally were sacrificed at 10 weeks post-treatment. Spinal cords wer
treatment groups have similar levels of spinal cord inflammation, demyelin
mid-thoracic level axons was compared across treatment groups, HIgM12-t
axons than the control IgM- and PBS-treated groups (P = 0.03 and P = 0.018
were analyzed, HIgM12-treated mice had more small-caliber (1 to 4 μm2, P
axons than the PBS-treated mice. HIgM12-treated mice had more medium
axons than the control IgM-treated mice. Pathology analysis was performeddid not show any differences across groups (Additional
file 1: Figure S1). Brainstem pathology was equivalent
across groups (P = 0.51, ANOVA on ranks) (Figure 1C).
Plotting individual NAA concentrations against corre-
sponding brainstem pathological scores (Figure 1D) yielded
no significant correlation (P = 0.59). We then analyzed the
number of animals in each group with improved NAA
concentrations 10 weeks after treatment. As a selection
criterion, we used a minimum of ≥2 times the baseline
standard error of the mean (SEM). NAA concentrations
improved in 1 of the 10 mice in the control IgM-treated
group, 1 of the 11 mice in the PBS-treated group, and 11
of the 13 mice in the HIgM12-treated group (Figure 1E).
Fisher’s exact test showed this was highly significant
(HIgM12 vs control IgM, P < 0.001; HIgM12 vs PBS,
P < 0.001; and control IgM vs PBS, P = 0.39): 84% of
mice treated with HIgM12 showed a positive response
(Additional file 2: Figure S2).
We tested whether improved NAA concentrations in
HIgM12-treatedmice correlated with spinal cord pathology
at the 10-week time point. Ten plastic-embedded cross
sections from each mouse were scored for inflamma-
tion, demyelination, and remyelination. Pathological
scores were similar across all three groups of mice
(Figure 2A). We then counted axons from mid-thoracic
(T6) spinal cord sections. Six areas encompassing
approximately 400,000 μm2 of white matter were
sampled from each mouse, and the total numbers of
mid-thoracic axons were compared across treatment
groups. HIgM12-treated mice with improved NAA
concentrations contained more axons than the control
IgM (17,524 ± 376 vs 15,488 ± 832) and PBS (17,524 ±
376 vs 15,198 ± 485) treated groups (Figure 2B). Detailed
analysis of axons distribution revealed that HIgM12-
treated mice had greater preservation of axons of all sizeses spinal cord axons. (A) The same mice used to collect MR spectra
e removed and processed for morphology analysis. Mice from all three
ation, and remyelination pathology. (B) When the total number of
reated mice with improved NAA concentrations also contained more
respectively, one-way ANOVA). (C) When axons of different calibers
= 0.039, one-way ANOVA) and medium-caliber (4 to 10 μm2, P = 0.037)
-caliber (4 to 10 μm2, P = 0.031) and large-caliber (>10 μm2, P = 0.028)
blinded to the experimental groups.
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ANOVA), medium-caliber (4 to 10 μm2, P = 0.037), and
large-caliber axons (>10 μm2, P = 0.028) (Figure 2C).
Discussion
In this study, we demonstrate that a neuron-targeting
human antibody is therapeutic in a progressive model of
inflammatory demyelinating disease. It is generally very
difficult to alter progression of neuropathology and
neurologic deficits in the TMEV model. In the past, we
documented that some human IgMs reactive to the sur-
face of oligodendrocytes remyelinate spinal cord lesions
in both the TMEV model of MS and in the lysolecithin-
induced demyelination model [19,20]. Using retrograde
tracing of demyelinated spinal cord axons, neuron cell
bodies in the brainstem labeled with fluorescent markers
indicating death or dysfunction were reduced [21]. This
led to the concept to use brainstem NAA concentration
as a sensitive marker to detect axon dysfunction well
before it is evident histologically [12].
Here, we examined whether treatment with neuron-
binding human antibody, HIgM12, alters brainstem
NAA concentrations in SJL mice at the stage of maximal
demyelination prior to significant axonal loss. A single
administration of HIgM12 given at 90 dpi improved
brainstem NAA concentrations significantly at both 5
and 10 weeks post-treatment. It is important to note that
at the 10-week time point brainstem pathological scores
were equivalent across groups, suggesting that brainstem
pathology had no influence on NAA concentrations. We
clearly find that a single administration of HIgM12 is
sufficient for improved brainstem NAA concentrations
in the TMEV model, but a single dose may not be the
optimum treatment. Treatment with multiple doses of
HIgM12 in animal models is however hampered due to
strong anti-human antibody responses with subsequent
administrations that likely inactivate HIgM12 in circu-
lation. The human IgM used in this study is available
as a GLP grade product suitable for translation to
human trials. Multiple doses of HIgM12 to treat human
neurodegeneration may significantly enhance efficacy
in patients greater than in disease models’.
We previously showed that a consistent 1-μm cross
section from the spinal cord can be used for axon
frequency analysis [15]. Using mid-thoracic sections,
we found that HIgM12-treated group in this study had
more axons of all calibers. Upon further analysis, we
determined that medium-caliber axons, which repre-
sent the largest population of axons, were primarily
preserved. We also found significant differences in the
small- and large-axon bins between the HIgM12 and
PBS groups and between HIgM12 and control IgM,
respectively. One possible explanation for greater num-
bers of small- and medium-caliber axons is large-caliber axons reduce their diameter due to atrophy.
This finding supports our previous observation of
shrinking of large-caliber axons in two independent
studies in different mouse strains [22,23].
Our data also suggests that demyelination may be a
necessary, but insufficient condition for neurologic
deficits associated with demyelinating diseases. The
primary goal of neuroprotection is to sustain the func-
tional integrity of neurons and limit dysfunction. MR
spectroscopy and axon-count analyses provide strong
evidence that HIgM12 affected neuronal viability through
the preservation of axons, despite equivalent levels of de-
myelination across treatment groups. Likewise, perforin-
deficient mice with a similar degree of demyelination
also had significantly more mid-thoracic axons com-
pared to wild-type littermate controls [16]. Our findings
are consistent with axonal damage occurring inde-
pendently of chronic demyelination. This concept was
suggested by several studies of gray matter lesions and
meningeal infiltrates in both human brain and genetically
manipulated mice [24-28].
In conclusion, our results provide the first evidence
for antibody-mediated axon protection in a mouse
model of progressive MS. The precise mode of action
of the antibody is currently under investigation. We
hypothesize that treatment with HIgM12 directly pro-
tects spinal cord axons and indirectly protects neurons
in the brainstem, which may underlie brainstem NAA
concentrations.Additional files
Additional file 1: Figure S1. Brain pathology was similar across treatment
groups. Individual brain pathology scores in all three treatment groups were
collected without knowledge of the treatment groups. Brain pathology was
quantified using five-point grading system. Overall pattern of individual
pathological scores from different brain regions showed no major
differences among the three treatment groups. Statistical comparison
revealed no differences (P = 0.144, one-way Kruskal-Wallis ANOVA).
Additional file 2: Figure S2. Majority of HIgM12-treated mice show
improved NAA concentrations in the brainstem. Individual NAA concentrations
were calculated at three different time points: baseline, 5 weeks, and 10weeks
post-treatment. Eleven of the 13mice (84.6%) in the HIgM12-treated group
showed an upward trend for NAA concentrations at 5- and 10-week time points,
whereas only 1mouse per group showed improvedNAA concentrations in the
control groups (N= 10, control IgM;N= 11, PBS).Abbreviations
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